Compassionate use of <scp>long‐acting</scp> cabotegravir plus rilpivirine for people living with <scp>HIV</scp>‐1 in need of parenteral antiretroviral therapyRonald D’Amico, Annemiek de Ruiter, Santiago Cenoz Gomis et al.|HIV Medicine|2022Cited by 46
Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studiesSharon Walmsley, Mounir Ait‐Khaled, Princy Kumar et al.|AIDS Research and Therapy|2024Cited by 11
1559. Healthcare Staff Perceptions of Feasibility and Acceptability on Implementing Injectable HIV Pre-exposure Prophylaxis into Standard of Care: Baseline Results from the PrEP Implementation Study for Cabotegravir Long Acting for Men in the Real World (PILLAR)Julian A Torres, Nanlesta Pilgrim, Dima Dandachi et al.|Open Forum Infectious Diseases|2023Cited by 0